quinta-feira, 29 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· October 20, 2026

Mercantile Bank forecasts 5%-7% annualized 4Q loan growth as it projects $0.6M quarterly cost reduction starting April 1, 2027

View original at seekingalpha.com

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Customer hesitancy on swaps as rates have popped up contributes to noninterest income variability

    60% confidence
  • Q3 tax rate increase was due to a lower level of net benefits from transferable energy tax credits; effective rate 16.8%

    60% confidence
  • NIM improved to 3.73% in Q3 2026 from 3.49% in Q3 2025 on lower cost of funds from the Eastern acquisition and deposit base refinement including lower broker deposits

    60% confidence
  • Deposit betas on nonmaturing deposits are the tricky part; goal is to be agnostic to rate changes with margin relatively stable, maybe a small increase, in 2027

    60% confidence
  • Lending commitments hit a 5-quarter high of $589M; nonperforming assets were 14 bps of total assets; past dues were 3 bps of loans

    60% confidence
  • Expects average Fed cash still in the upper $300s million in Q4 (from $425M); Southeast Michigan team grew to about half a dozen commercial callers

    60% confidence
  • Total deposits rose 17% over 12 months while CDs declined about $180M due to brokered CD runoff

    60% confidence
  • Starting April 1, 2027, a $0.6M quarterly reduction in data processing and statement processing costs is projected

    60% confidence
  • Market conditions remain volatile, making forecasting difficult; deposit betas are impossible to model accurately; timing of Southeast Michigan talent additions is nearly impossible to forecast

    60% confidence
  • Excess-cash-flow paydowns are very difficult to predict

    60% confidence
  • Borrower confidence has not changed materially; the NPL pickup is a few drops of rain with no systemic issues

    60% confidence
  • 2026 is a year of investment in people and technology, including a change in core systems provider

    60% confidence
  • Disruption in the market creates opportunity to hire people and add customers; Mercantile will continue to invest if opportunities exist

    60% confidence
  • Deposit growth should roughly parallel loan growth

    60% confidence
  • Projected Q4 federal tax rate of approximately 17%

    60% confidence
  • NIM expected to remain relatively stable across rate environments, with a higher Q4 margin from loan growth, lower Fed cash and maturing low-yield CRE loans and investments

    60% confidence
  • Q4 noninterest income step-down is driven by seasonal mortgage income and swap lumpiness

    60% confidence
  • Commercial loans increased 9% from prior year-end; refinancing, asset sales and excess cash flow paydowns totaled $448M for the 9 months ended 9/30/2026

    60% confidence
  • Securities portfolio duration is about 4 years; Q4 charge-off timing was total coincidence

    60% confidence
  • Net loan growth projected at 5%-7% annualized for Q4 2026, predicated on no change in the federal funds rate

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,994
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,994 factos verificados com a fonte5,503 documentos-fonte arquivados
Consulte estes dados → isubstrate.com